Virotherapy, Cell-based Therapy and Gene Therapy with Non-Replicating Oncolytic Virus Particle (HVJ-E/GEN0101) for the Treatment of CancersTuesday, 12 November 2019 at 09:10 Add to Calendar ▼2019-11-12 09:10:002019-11-12 10:10:00Europe/LondonVirotherapy, Cell-based Therapy and Gene Therapy with Non-Replicating Oncolytic Virus Particle (HVJ-E/GEN0101) for the Treatment of CancersCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com HVJ-E/GEN0101 is an inactivated virus particle derived from murine parainfluenza virus HVJ (Hemagglutinating virus of Japan). It has been originally developed as a vector for gene therapy. We discovered the virus particle itself has an activity to induce cancer-cell specific apoptosis and necroptosis. It also induces innate and adaptive immunities necessary to attack cancer cells. The active ingredient is a single strand RNA fragment derived from genomic RNA of the virus. It binds to an intracellular nucleic acid receptor RIG-I and induces expressions of cytokines, chemokines and apoptosis-related genes in vitro and in vivo. We conduced safety studies using Cynomolgus monkeys and started investigator initiated clinical studies in Osaka University to develop HVJ-E as a new drug for cancer immune- and viro-therapies. To date five phase I or I/IIa investigator initiated clinical studies has been finished. The targets cancers are melanoma, prostate cancer and malignant pleural mesothelioma. In these studies, the safety, efficacy and mechanism of actions of the drug have been evaluated. No serious adverse event related to the drug was observed and safety of the drug is confirmed in clinical. Reduction and eradication of tumor lesions were observed in a dose dependent manner. Induction of innate and adaptive immunities after administration of HVJ-E was observed in clinical, suggesting that the efficacy is mediated by immune reactions. The efficacy is expected to be increased in combination with anti-PD-1 antibody therapy, we are now conducting two phase II studies of melanoma and malignant pleural mesothelioma for the evaluation of efficacy of combinational therapy. |